Literature DB >> 32065805

Changes to Ventilation, Vocalization, and Thermal Nociception in the Pink1-/- Rat Model of Parkinson's Disease.

Rebecca A Johnson1, Cynthia A Kelm-Nelson2, Michelle R Ciucci2,3,4.   

Abstract

BACKGROUND: Individuals with Parkinson's disease (PD) experience significant vocal communication deficits. Findings in the Pink1-/- rat model of early-onset PD suggest that ultrasonic vocal communication is impaired early, progressively worsens prior to nigrostriatal dopamine depletion, and is associated with loss of locus coeruleus neurons, brainstem α-synuclein, and larynx pathology. Individuals with PD also demonstrate ventilatory deficits and altered sensory processing, which may contribute to vocal deficits.
OBJECTIVE: The central hypothesis is that ventilatory and sensory deficits are present in the early disease stages when limb and vocal motor deficits also present.
METHODS: Pink1-/- rats were compared to wildtype (WT) controls at longitudinal timepoints. Whole-body flow through plethysmography was used to measure ventilation in the following conditions: baseline, hypoxia, and maximal chemoreceptor stimulation. Plantar thermal nociception, and as a follow up to previous work, limb gait and vocalization were analyzed. Serotonin density (5-HT) in the dorsal raphe was quantified post-mortem.
RESULTS: Baseline breathing frequencies were consistently higher in Pink1-/- rats at all time points. In hypoxic conditions, there were no significant changes between genotypes. With hypercapnia, Pink1-/- rats had decreased breathing frequencies with age. Thermal withdrawal latencies were significantly faster in Pink1-/- compared with WT rats across time. No differences in 5-HT were found between genotypes. Vocal peak frequency was negatively correlated to tidal volume and minute ventilation in Pink1-/- rats.
CONCLUSION: This work suggests that abnormal nociceptive responses in Pink1-/- rats and ventilatory abnormalities may be associated with abnormal sensorimotor processing to chemosensory stimuli during disease manifestation.

Entities:  

Keywords:  Parkinson’s disease; Pink1; rat; sensory; ultrasonic vocalization; ventilation

Mesh:

Substances:

Year:  2020        PMID: 32065805      PMCID: PMC8142388          DOI: 10.3233/JPD-191853

Source DB:  PubMed          Journal:  J Parkinsons Dis        ISSN: 1877-7171            Impact factor:   5.568


  85 in total

Review 1.  Nonmotor disturbances in Parkinson's disease.

Authors:  Claudio L Bassetti
Journal:  Neurodegener Dis       Date:  2010-12-23       Impact factor: 2.977

2.  Decreased approach behavior and nucleus accumbens immediate early gene expression in response to Parkinsonian ultrasonic vocalizations in rats.

Authors:  Joshua D Pultorak; Cynthia A Kelm-Nelson; Lauren R Holt; Katherine V Blue; Michelle R Ciucci; Aaron M Johnson
Journal:  Soc Neurosci       Date:  2015-09-14       Impact factor: 2.083

3.  Identification of multiple call categories within the rich repertoire of adult rat 50-kHz ultrasonic vocalizations: effects of amphetamine and social context.

Authors:  Jennifer M Wright; Jim C Gourdon; Paul B S Clarke
Journal:  Psychopharmacology (Berl)       Date:  2010-05-06       Impact factor: 4.530

4.  Abnormal ventilatory control in Parkinson's disease--further evidence for non-motor dysfunction.

Authors:  Leigh M Seccombe; Hugh L Giddings; Peter G Rogers; Alastair J Corbett; Michael W Hayes; Matthew J Peters; Elizabeth M Veitch
Journal:  Respir Physiol Neurobiol       Date:  2011-09-29       Impact factor: 1.931

Review 5.  Cranial and related sensorimotor impairments in rodent models of Parkinson's disease.

Authors:  Sheila M Fleming; Tim Schallert; Michelle R Ciucci
Journal:  Behav Brain Res       Date:  2012-02-28       Impact factor: 3.332

6.  Multimodal Swallowing Evaluation with High-Resolution Manometry Reveals Subtle Swallowing Changes in Early and Mid-Stage Parkinson Disease.

Authors:  Corinne A Jones; Michelle R Ciucci
Journal:  J Parkinsons Dis       Date:  2016       Impact factor: 5.568

7.  Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin.

Authors:  Jeehye Park; Sung Bae Lee; Sungkyu Lee; Yongsung Kim; Saera Song; Sunhong Kim; Eunkyung Bae; Jaeseob Kim; Minho Shong; Jin-Man Kim; Jongkyeong Chung
Journal:  Nature       Date:  2006-05-03       Impact factor: 49.962

8.  Progression of dysarthria and dysphagia in postmortem-confirmed parkinsonian disorders.

Authors:  J Müller; G K Wenning; M Verny; A McKee; K R Chaudhuri; K Jellinger; W Poewe; I Litvan
Journal:  Arch Neurol       Date:  2001-02

9.  Characterization of 50-kHz ultrasonic vocalizations in male and female rats.

Authors:  Marilyn Y McGinnis; M Vakulenko
Journal:  Physiol Behav       Date:  2003-10

10.  Early occurrence of inspiratory muscle weakness in Parkinson's disease.

Authors:  Guillaume Baille; Thierry Perez; David Devos; Valérie Deken; Luc Defebvre; Caroline Moreau
Journal:  PLoS One       Date:  2018-01-12       Impact factor: 3.240

View more
  4 in total

1.  Manipulation of vocal communication and anxiety through pharmacologic modulation of norepinephrine in the Pink1-/- rat model of Parkinson disease.

Authors:  Jesse D Hoffmeister; Cynthia A Kelm-Nelson; Michelle R Ciucci
Journal:  Behav Brain Res       Date:  2021-10-28       Impact factor: 3.332

Review 2.  Respiratory Abnormalities in Parkinson's Disease: What Do We Know from Studies in Humans and Animal Models?

Authors:  Katarzyna Kaczyńska; Magdalena Ewa Orłowska; Kryspin Andrzejewski
Journal:  Int J Mol Sci       Date:  2022-03-23       Impact factor: 5.923

Review 3.  Rat Models of Vocal Deficits in Parkinson's Disease.

Authors:  Maryann N Krasko; Jesse D Hoffmeister; Nicole E Schaen-Heacock; Jacob M Welsch; Cynthia A Kelm-Nelson; Michelle R Ciucci
Journal:  Brain Sci       Date:  2021-07-13

4.  Quantification of brainstem norepinephrine relative to vocal impairment and anxiety in the Pink1-/- rat model of Parkinson disease.

Authors:  Jesse D Hoffmeister; Cynthia A Kelm-Nelson; Michelle R Ciucci
Journal:  Behav Brain Res       Date:  2021-08-04       Impact factor: 3.352

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.